Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06525181

AI as an Aid for Weekly Symptom Intake in Radiotherapy

Evaluation of AI-Enhanced Symptom Summarization in Weekly Radiotherapy Consultations: A Comparative Study

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
200 (estimated)
Sponsor
jaide · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The study investigates the use of artificial intelligence (AI) and large language models (LLMs) to enhance the efficiency and accuracy of weekly treatment consultations (OTVs) in radiotherapy. It hypothesizes that an AI-enabled symptom summary tool will match traditional medical review methods in accuracy while saving time. The study includes patients undergoing pelvic radiotherapy and excludes those with pelvic reirradiation or who have undergone surgery. Patients will receive both standard and AI-assisted weekly consultations, with AI summaries generated using the OpenAI GPT-4 API. Blinded oncologists will compare the accuracy and quality of the AI-generated and doctor-generated summaries, while patients and doctors will rate these summaries. The primary objective is to evaluate the accuracy and time efficiency of AI-assisted symptom summaries compared to traditional methods.

Detailed description

This clinical trial is a comparative study designed to evaluate the accuracy and time efficiency of an AI-enabled symptom summary tool in comparison to traditional medical review methods in patients undergoing radiotherapy in the pelvic region. Hypothesis: The AI-enabled symptom summary tool is hypothesized to be non-inferior in accuracy to traditional medical review methods and to save time in the process. Primary Outcome: Accuracy of Documentation: The quality of the documentation will be evaluated using the Physician Documentation Quality Instrument-9 (PDQI-9), a validated questionnaire that assesses nine key elements of documentation quality: completeness, correctness, consistency, comprehensibility, relevance, organization, conciseness, formatting, and overall impression. Blinded specialist doctors will use the PDQI-9 to evaluate both AI-generated and traditional summaries, assigning scores from 1 to 10. Secondary Outcomes: Time Efficiency: The time required to complete the AI-enabled and traditional consultations will be recorded and compared. Physician Satisfaction: A custom-designed satisfaction questionnaire will be administered to the physicians participating in the study. This questionnaire will include Likert-scale questions to rate various aspects of satisfaction, including ease of use, time efficiency, accuracy perception, and overall satisfaction. Patient Satisfaction: A custom-designed satisfaction questionnaire will be administered to the patients participating in the study. This questionnaire will include Likert-scale questions to rate various aspects of satisfaction, including clarity and understanding, perceived accuracy, engagement and interaction, and overall satisfaction. Methodology: Patient Selection: Patients meeting the inclusion criteria will be selected for participation. Exclusion criteria will be applied to eliminate cases of pelvic reirradiation or prior operations in the pelvic region. Consultation Process: Patients will undergo a standard weekly consultation with a doctor. In the same week, each patient will also have a separate consultation with a different doctor. During this second consultation, a symptom questionnaire will be completed under medical supervision. The resulting summary from this questionnaire will be generated using the OpenAI GPT-4 API.

Conditions

Interventions

TypeNameDescription
OTHERGenerative Artificial IntelligenceGen AI assisted symptom intake summarization
OTHERStandard weekly symptom intakeStandard weekly symptom intake performed by a physician

Timeline

Start date
2024-07-22
Primary completion
2024-11-01
Completion
2024-12-15
First posted
2024-07-29
Last updated
2024-10-10

Locations

1 site across 1 country: Brazil

Source: ClinicalTrials.gov record NCT06525181. Inclusion in this directory is not an endorsement.